#cll

🔎 Exploring CLL clinical trials just got easier! The CLLAN Clinical Trials Search Hub 2.0 launches Monday with AI-powered features. Stay tuned! #CLL #ClinicalTrialsHub #PatientAdvocacy #CLLAN #CLLResearch #ClinicalTrials

🎙️ NEW PODCAST | Beyond BTK inhibition in #CLL Experts discuss emerging BTK degraders, overcoming treatment resistance, novel combinations & the evolving role of CAR-T and bispecific antibodies. 🎧 Listen now: #CLLsm #Leukemia #Leusm #ImmunoOnc Intended for healthcare professionals. VJHemOnc's CLL Channel is supported by life sciences companies (listed on the Channel page), which have no influence over the content.

Abstracts are now public for #ASH26 Check out an oral abstract to be presented by Erica Lamkin from our lab @SylvesterCancer on Macrocyclization of BTK inhibitors to overcome resistance in #CLL ASH® ANNUAL PROGRAM

Submit an abstract to showcase your #CLL research at #iwCLL2023! The event is taking place October 6-9, 2023 in Boston, MA. Click here to submit your abstract: For additional program details & updates, visit

📬 Did you catch our October newsletter? From #CLL Horizons 2026 highlights to latest updates,member news and a sneak peek at CLL Clinical Trials Hub 2.0, there’s plenty to discover!👉 #CLLAN #PatientAdvocacy #CLLCommunity #CLLMatters #Newsletter

CLL. Takeaway points @TheIACH @Mohty_EBMT @NStockerSAT #CLL #lymphoma #lymsm

🔴 We are Live! Chemo-free Therapy of Relapsed CLL with Nicolas Stocker Join the webinar → @NStockerSAT @Mohty_EBMT

➡️➡️Big CLL news! Munir et al OS and PFS adv for MRD driven I&V over ibrutinib in 1L #CLL #EHA2025 Congrats to all FLAIR trial 🇬🇧group Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | New England Journal of Medicine

🐭 Can mitochondrial DNA mutations track lineage in murine cancer models❓ Together w/ @etenhacken plus the mtDNA experts @LeifLudwig and @CalebLareau we investigated this question with mtscATAC-seq using Elisa's #CLL and #RS models. Out now in @CR_AACR./1

Significant progress in #CLL therapy over the last decade as highlighted in this review article in @TheLancet by @NitinJainMD @wwierda Susan O’Brien @MDAndersonNews #Leukemia #leusm

Very happy to share our retrospective study of TP53-altered CLL receiving 1L BTKi-based txt just pub in @AjHematology Mentored by amazing @NitinJainMD and collab w/@kanagalshamanna + Dr Guilin Tang #CLL #lymsm #leusm @MDAndersonNews @wwierda @DrHKantarjian

🏆 Honored that our study on ARI-0001 (varnimcabtagene autoleucel) in high-risk #CLL and #RichterTransformation has been selected for an oral presentation at #ASH26 in📍New Orleans, and recognized with an ASH Abstract Achievement. @ValentinOrtizMD @JulioDelgadoHem

🚀 It's here! Explore the new CLLAN Clinical Trials Search Hub 2.0 with AI summaries, easy navigation & more! 👉 #CLL #ClinicalTrialsHub #PatientAdvocacy #CLLAN #ClinicalResearch #CLLResearch #ClinicalTrials

This #JACCCardioOnc state-of-the-art review examines the current state of evidence, including incidence rates, risk factors, mechanisms, & management strategies of CV toxicities w/ #BTK inhibitors & other #CLL therapies. #CardioOnc #leusm

Coming soon: MAJIC ph3 trial for 1L #CLL in collaboration with @anthonymatomd @jeff_sharman @AstraZeneca @abbvie @genentech #ASH2021

Check out our latest work on transcriptomic profiles of #CLL, drivers of MRD response and 5-year results from CLL14 – all out today in one paper @NatureComms : Key results in a brief 🧵

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in #CLL

Support my cancer fight! I’m still alive and not giving up.This life is mines. Battling breast cancer and leukemia has made the last three years of my so miserable. But I’m not done living #CancerAwareness #donations #cll #twitterphilanthropist #gofundme

We had a great time in Atlanta at #ASH21! ICYMI – check out our virtual medical booth, where you can access our scientific presentations and learn about our latest #hematology research #CLL #MCL

Excited to attend #ASCO24 next week and represent @MSKCancerCenter Thanks @ASCO for inviting me to chair the #lymphoma #CLL rapid abstract session. Looking forward to discussing great science with @DanilovLab and catching up with friends! Join us! June 2, 4.30- 6PM CDT E450b

How is biomarker testing informing first-line treatment decisions in #CLL? A new real-world study, developed in collaboration with the CLL Society and informed by patient advisors, examines del(17p)/TP53 and IGHV testing and its association with treatment patterns and clinical outcomes. Read more: